COMBINATION THERAPEUTIC DRUG FOR ACUTE MYELOID LEUKEMIA

Disclosed are a drug and method for treating acute myeloid leukemia by means of combined administration of a multi-target kinase inhibitor compound I or a pharmaceutically acceptable salt thereof with daunorubicin and cytarabine. The combination of compound I or the pharmaceutically acceptable salt thereof with daunorubicin and cytarabine can significantly inhibit the proliferation of human leukemia cells MV-4-11 and MOLM-13, produces a synergistic effect, and has a combined efficacy which is better than that of a scheme only using daunorubicin and cytarabine, and treated patients will have a longer survival period. The potential of the combination therapeutic scheme in prognosis improvement is much greater than the risk of potential toxicity thereof, and the scheme has good clinical application prospects. L'invention concerne un médicament et un procédé de traitement de la leucémie myéloïde aiguë au moyen d'une administration combinée d'un composé inhibiteur de kinases multi-cible I ou d'un sel pharmaceutiqu